Adding Maraviroc to Suppressive ART for Suboptimal CD4 Recovery

ACTG 5256
Adding Maraviroc to Suppressive ART for Suboptimal CD4 Recovery

ACTG 5256: Study Design

Study Design: ACTG 5256

- **Background**: Single-arm, pilot trial of adding maraviroc to suppressive ART in setting of suboptimal CD4 recovery to evaluate whether maraviroc intensification is associated with an increase of at least 20 cells/mm$^3$ in the CD4 count.

- **Inclusion Criteria (n = 34)**
  - HIV-1 infected adults
  - Receiving stable ART with HIV RNA below limit of detection for at least 48 weeks
  - Stable but suboptimal CD4 recovery over previous year (<250 cells/mm$^3$ and slope of annual change between -20 and 20 cells/mm$^3$)
  - No prior exposure to a CCR5 antagonist

- **Single Treatment Arm**
  - Maraviroc added to ART for 24 weeks, then stopped and patient followed another 24 weeks

Adding Maraviroc to Suppressive ART for Suboptimal CD4 Recovery

ACTG 5256: Results

Change in CD4 Count with Maraviroc Intensification

*The median increase in CD4(+) T-cell count from baseline to week 24 was 12 cells/mm$^3$.

Conclusions: “Adding maraviroc to suppressive ART for 24 weeks was not associated with an increase in CD4+ T-cell counts of at least 20 cells/mm³. Further studies of CCR5 antagonists in the dampening of immune activation associated with HIV infection are warranted.”
Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.